Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis

2001 ◽  
Vol 6 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Etsuji Shiota ◽  
Kuniyoshi Tsuchiya ◽  
Kazuhiro Yamaoka ◽  
Osamu Kawano
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Etidronate Disodium

Etidronate disodium in postmenopausal osteoporosis

1976 ◽  
Vol 20 (5) ◽  
pp. 593-604 ◽  
Author(s):  
Robert P. Heaney ◽  
Paul D. Saville
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Etidronate Disodium

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

2014 ◽  
Vol 23 (01) ◽  
pp. 49-55
Author(s):  
L. C. Hofbauer ◽  
D. Felsenberg ◽  
M. Amling ◽  
A. Kurth ◽  
P. Hadji
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Osteoporosis ◽  
Primary Outcome ◽  
Osteoporosis Treatment ◽  
Secondary Outcome ◽  
Matched Pairs ◽  
Fracture History ◽  
Baseline Characteristics ◽  
Study Inclusion

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

Zoledronate in the treatment of postmenopausal osteoporosis

2007 ◽  
Vol 115 (S 1) ◽  
Author(s):  
H Stracke ◽  
S Wamsler ◽  
A Liebchen ◽  
RG Bretzel
Keyword(s):  
Postmenopausal Osteoporosis

Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis

2014 ◽  
Author(s):  
Svetlana Yureneva ◽  
Oksana Yakushevskaya ◽  
Andrey Donnikov ◽  
Sergey Kuznetzov ◽  
Svetlana Mullambaeva ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

2014 ◽  
Author(s):  
Fatma Gossiel ◽  
Kim Naylor ◽  
Eugene McCloskey ◽  
Nicola Peel ◽  
Jennifer Walsh ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Bisphosphonate Treatment
Sign in / Sign up

Export Citation Format

Share Document